Talquetamab–Daratumumab in Relapsed or Refractory Myeloma | NEJM
Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1–2 trials, with a lim...
nejm.org